Kazumichi Furuyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kazumichi Furuyama has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Kiriko Kaneko
Department of Molecular Biochemistry, Iwate Medical University, Yahaba, Iwate, Japan
5 shared publicationsYoshiko Kubota
Department of Molecular Biochemistry, Iwate Medical University, Yahaba, Iwate, Japan
4 shared publicationsKazumi Nomura
Department of Molecular Biochemistry, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan
2 shared publications- Ko Suzuki
Department of Molecular Biochemistry Iwate Medical University Yahaba Iwate Japan
2 shared publications Costantine Chasama Kamata
Department of Molecular Biochemistry, Iwate Medical University, Yahaba, Iwate, Japan
1 shared publicationCostantine Kamata
Iwate Medical University
1 shared publication
Latest Publications
- Open Access
- 3 September 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (10) , 105210
CLPX regulates mitochondrial fatty acid β-oxidation in liver cells
- 3 September 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (10) , 105210
Open AccessCLPX regulates mitochondrial fatty acid β-oxidation in liver cells
- Open Access
- 26 April 2022
- Published by Springer Nature in Research Square
CLPX regulates mitochondrial fatty acid β-oxidation by modulating protein complex formation in liver cells
Mitochondrial fatty acid oxidation (β-oxidation) is an essential metabolic process for energy production in eukaryotic cells, but the regulatory mechanisms of this pathway are largely unknown. In the present study, we found that several enzymes involved in β-oxidation are associated with CLPX, the AAA + unfoldase that is a component of the mitochondrial matrix protease ClpXP. Deletion of the CLPX gene increased β-oxidation activity in human hepatic cells but did not change the protein levels of enzymes involved in β-oxidation. Moreover, glucagon treatment resulted in decreased CLPX levels and increased β-oxidation activity in these cells, while the expression levels of enzymes involved in β-oxidation were not altered. Coimmunoprecipitation experiments revealed that glucagon treatment induced the dissociation of several β-oxidation-related enzymes from CLPX, suggesting that CLPX regulates β-oxidation by modulating the protein complex formation of enzymes catalyzing β-oxidation.
- 26 April 2022
- Published by Springer Nature in Research Square
Open AccessCLPX regulates mitochondrial fatty acid β-oxidation by modulating protein complex formation in liver cells
Mitochondrial fatty acid oxidation (β-oxidation) is an essential metabolic process for energy production in eukaryotic cells, but the regulatory mechanisms of this pathway are largely unknown. In the present study, we found that several enzymes involved in β-oxidation are associated with CLPX, the AAA + unfoldase that is a component of the mitochondrial matrix protease ClpXP. Deletion of the CLPX gene increased β-oxidation activity in human hepatic cells but did not change the protein levels of enzymes involved in β-oxidation. Moreover, glucagon treatment resulted in decreased CLPX levels and increased β-oxidation activity in these cells, while the expression levels of enzymes involved in β-oxidation were not altered. Coimmunoprecipitation experiments revealed that glucagon treatment induced the dissociation of several β-oxidation-related enzymes from CLPX, suggesting that CLPX regulates β-oxidation by modulating the protein complex formation of enzymes catalyzing β-oxidation.
- 1 September 2018
- Published by Elsevier in Experimental Hematology
- Vol. 65, 57-68.e2
Establishment of a cell model of X-linked sideroblastic anemia using genome editing
- 1 September 2018
- Published by Elsevier in Experimental Hematology
- Vol. 65, 57-68.e2
Establishment of a cell model of X-linked sideroblastic anemia using genome editing
- 14 November 2017
- Published by Springer Nature in International Journal of Hematology
- Vol. 107 (1) , 44-54
Iron metabolism in erythroid cells and patients with congenital sideroblastic anemia
Sideroblastic anemias are anemic disorders characterized by the presence of ring sideroblasts in a patient’s bone marrow. These disorders are typically divided into two types, congenital or acquired sideroblastic anemia. Recently, several genes were reported as responsible for congenital sideroblastic anemia; however, the relationship between the function of the gene products and ring sideroblasts is largely unclear. In this review article, we will focus on the iron metabolism in erythroid cells as well as in patients with congenital sideroblastic anemia.
- 14 November 2017
- Published by Springer Nature in International Journal of Hematology
- Vol. 107 (1) , 44-54
Iron metabolism in erythroid cells and patients with congenital sideroblastic anemia
Sideroblastic anemias are anemic disorders characterized by the presence of ring sideroblasts in a patient’s bone marrow. These disorders are typically divided into two types, congenital or acquired sideroblastic anemia. Recently, several genes were reported as responsible for congenital sideroblastic anemia; however, the relationship between the function of the gene products and ring sideroblasts is largely unclear. In this review article, we will focus on the iron metabolism in erythroid cells as well as in patients with congenital sideroblastic anemia.
- Open Access
- 1 September 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (39) , 20516-20529
Novel Mechanisms for Heme-dependent Degradation of ALAS1 Protein as a Component of Negative Feedback Regulation of Heme Biosynthesis
- 1 September 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (39) , 20516-20529
Open AccessNovel Mechanisms for Heme-dependent Degradation of ALAS1 Protein as a Component of Negative Feedback Regulation of Heme Biosynthesis
- Open Access
- 9 August 2013
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 99 (2) , 252-261
Identification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia
Erythroid-specific 5-aminolevulinate synthase (ALAS2) is the rate-limiting enzyme for heme biosynthesis in erythroid cells, and a missense mutation of the ALAS2 gene is associated with congenital sideroblastic anemia. However, the gene responsible for this form of anemia remains unclear in about 40% of patients. Here, we identify a novel erythroid-specific enhancer of 130 base pairs in the first intron of the ALAS2 gene. The newly identified enhancer contains a cis-acting element that is bound by the erythroid-specific transcription factor GATA1, as confirmed by chromatin immunoprecipitation analysis in vivo and by electrophoretic mobility shift assay in vitro. A promoter activity assay in K562 human erythroleukemia cells revealed that the presence of this 130-base pair region increased the promoter activity of the ALAS2 gene by 10–15-fold. Importantly, two mutations, each of which disrupts the GATA-binding site in the enhancer, were identified in unrelated male patients with congenital sideroblastic anemia, and the lower expression level of ALAS2 mRNA in bone marrow erythroblasts was confirmed in one of these patients. Moreover, GATA1 failed to bind to each mutant sequence at the GATA-binding site, and each mutation abolished the enhancer function on ALAS2 promoter activity in K562 cells. Thus, a mutation at the GATA-binding site in this enhancer may cause congenital sideroblastic anemia. These results suggest that the newly identified intronic enhancer is essential for the expression of the ALAS2 gene in erythroid cells. We propose that the 130-base pair enhancer region located in the first intron of the ALAS2 gene should be examined in patients with congenital sideroblastic anemia in whom the gene responsible is unknown.
- 9 August 2013
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 99 (2) , 252-261
Open AccessIdentification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia
Erythroid-specific 5-aminolevulinate synthase (ALAS2) is the rate-limiting enzyme for heme biosynthesis in erythroid cells, and a missense mutation of the ALAS2 gene is associated with congenital sideroblastic anemia. However, the gene responsible for this form of anemia remains unclear in about 40% of patients. Here, we identify a novel erythroid-specific enhancer of 130 base pairs in the first intron of the ALAS2 gene. The newly identified enhancer contains a cis-acting element that is bound by the erythroid-specific transcription factor GATA1, as confirmed by chromatin immunoprecipitation analysis in vivo and by electrophoretic mobility shift assay in vitro. A promoter activity assay in K562 human erythroleukemia cells revealed that the presence of this 130-base pair region increased the promoter activity of the ALAS2 gene by 10–15-fold. Importantly, two mutations, each of which disrupts the GATA-binding site in the enhancer, were identified in unrelated male patients with congenital sideroblastic anemia, and the lower expression level of ALAS2 mRNA in bone marrow erythroblasts was confirmed in one of these patients. Moreover, GATA1 failed to bind to each mutant sequence at the GATA-binding site, and each mutation abolished the enhancer function on ALAS2 promoter activity in K562 cells. Thus, a mutation at the GATA-binding site in this enhancer may cause congenital sideroblastic anemia. These results suggest that the newly identified intronic enhancer is essential for the expression of the ALAS2 gene in erythroid cells. We propose that the 130-base pair enhancer region located in the first intron of the ALAS2 gene should be examined in patients with congenital sideroblastic anemia in whom the gene responsible is unknown.